Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.
Read More
Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies.
Read More
Boehringer Ingelheim signs new deals with UK-based Evox Technologies and Roche.
Read More
Boehringer Ingelheim has signed a second deal focused on the development of RNA therapeutics for liver diseases.
Read More
GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s Spiolto Respimat.
Read More
